Comparing the current results to its competitors, Siga Technologies Inc reported Revenue decrease in the 2 quarter 2026 year on year by -49.45 %, despite the revenue increase by the most of its competitors of 12.76 %, recorded in the same quarter.
Siga Technologies Inc Net Income in the 2 quarter 2026 fell year on year by -22.88%, while most of its competitors have experienced a contraction in net income by -83.19 %.
Siga Technologies Inc's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industries are highly competitive and characterized by rapidly evolving technology. The company competes with major pharmaceutical firms, including Emergent BioSolutions Inc. and Bavarian Nordic A/S, particularly in the medical countermeasure sector. Additionally, academic institutions, governmental agencies, and other public and private research organizations conduct research and may commercialize products independently or through joint ventures. The company's product, TPOXX®, faces competition for government funding related to the development and procurement of medical countermeasures for various threats. Commercial opportunities could be affected if competitors develop superior products or if government funding and procurement practices change. The company must also comply with governmental procurement requirements, especially those of the U.S. Government, to compete effectively.
August 21, 2024
In a significant development within the pharmaceutical sector, SIGA Technologies, Inc. has been awarded a new contract by the U.S. Department of Defense (DOD) valued at approximately $9 million for the procurement of its antiviral drug TPOXX (tecovirimat). This announcement, made on August 21, 2024, marks the third contract award received by SIGA from the DOD in the past three years. The contract (number: W911SR24C0030) primarily encompasses the supply of oral formulations of TPOXX, alongside a smaller allocation of intravenous (IV) formulations.TPOXX has been recognized for its role in the treatment of orthopoxvirus infections, including smallpox, which is considered a potential bioweapon threat. The DOD ...
August 15, 2024
Topline Results from PALM 007 Study of SIGA s Tecovirimat in Treatment of Monkeypox (Mpox) Released: Implications and Future Directions The National Institutes of Health (NIH), through its National Institute of Allergy and Infectious Diseases (NIAID), recently announced the topline results from a preliminary analysis of the PALM 007 clinical trial (NCT05559099), which investigated the efficacy of SIGA s tecovirimat for treating Monkeypox Virus (mpox) in the Democratic Republic of the Congo (DRC). This article aims to provide an in-depth exploration of these results, analyze their implications for future mpox treatment strategies, and discuss the broader context of antiviral research. Monkeypox (mpox) is a z...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Sources:
Siga Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Siga Technologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
